Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine
Crossref DOI link: https://doi.org/10.1007/s11060-015-2002-z
Published Online: 2015-11-27
Published Print: 2016-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Heiland, D. H.
Masalha, W.
Franco, P.
Machein, M. R.
Weyerbrock, A.
Text and Data Mining valid from 2015-11-27